AI-Driven Cancer Diagnosis and Prediction With EHR

Launched by THE EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITY · Jan 19, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how artificial intelligence (AI) can help doctors identify and diagnose cancer more effectively by using a variety of health information from patients’ electronic health records (EHRs). The study aims to see if AI can analyze data like medical history, lab results, imaging scans, and even genetic information to improve cancer predictions. The trial is currently open for recruitment and is looking for participants of all ages, from newborns to adults, as long as they have complete health records and can provide informed consent.

To participate, individuals need to have access to detailed health records and should not have serious cognitive issues that would affect their ability to understand the study. For minors, parents or guardians will need to give consent. Those with incomplete health records, severe cognitive disorders, or certain health conditions like terminal illnesses, as well as pregnant women, are not eligible. Participants will be helping researchers understand how AI can be used to improve cancer diagnosis, which could lead to better outcomes for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1、Patients with comprehensive electronic health records (EHRs), including medical history, laboratory test results, imaging data, and genetic data (if available).
• • 2. Individuals without severe cognitive impairments or conditions that would prevent them from providing informed consent or participating in the study.
• • 3. Parents or guardians must provide informed consent for minors, while adult participants must provide informed consent for themselves.
• Exclusion Criteria:
• • 1. Patients with incomplete or missing key electronic health record data or insufficient follow-up data.
• • 2. Individuals with severe cognitive disorders or other terminal illnesses that would prevent meaningful participation.
• • 3. Pregnant women (although pediatric cancers are being considered, pregnant women would be excluded for safety reasons).